Inova Names Michael Maitland, M.D, Ph.D., Director of Therapeutics for the Inova Center for Personalized Health

Maitland will also serve as Associate Director of Cancer Therapeutics for the Inova Schar Cancer

FALLS CHURCH, VA – August 16, 2016 – Inova Health System is pleased to welcome Michael Maitland, M.D., Ph.D., where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health (ICPH) and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute (ISCI). Dr. Maitland came to Inova from the University of Chicago where he was the Co-Leader of the Cancer Developmental Therapeutics Program, Assistant Director of the Center for Personalized Therapeutics and Assistant Professor of Medicine in the Section of Hematology/Oncology and the Committee on Clinical Pharmacology and Pharmacogenomics. He brings broad expertise to Inova in human genetics, drug development, cardiovascular safety of new cancer drugs, clinical pharmacology consultations, and care of cancer patients with advanced metastatic disease.

“Dr. Maitland is a strong addition to the team, bringing substantial expertise in translational medicine and therapeutics research to develop improved methods of personalized therapy.” said Dr. Donald “Skip” Trump, CEO, Inova Schar Cancer Institute. “With clinical pharmacology (the evaluation of factors that determine the effectiveness and side effects of drugs) as the organizing principle, Dr. Maitland will facilitate learning and application of modern methods of personalized drug therapy, not only in cancer care, but also in other diseases.”

Dr. Maitland will work closely with Inova investigators, University partners, and regional and national biotechnology and pharmaceutical collaborators to ensure that Inova delivers the highest quality and value in clinical therapeutics science and incorporates this science into patient care throughout the Inova Health System. He is evaluating the development of new biomarkers to better personalize treatments as “adaptive, responsive therapy.”
Dr. Maitland earned his Bachelor of Science degree in Biology from Yale University, and his M.S. and Ph.D. in Microbiology and Immunology and M.D. at the Albert Einstein College of Yeshiva University. Dr. Maitland completed his Internal Medicine residency at the New York Presbyterian Hospital/Weill-Cornell Medical Center. Subsequently he worked as a fellow in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York before completing a joint fellowship in Medical Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago to. Dr. Maitland most recently served as Associate Director of the Clinical Pharmacology and Pharmacogenomics training program at University of Chicago, and has held multiple grants from the National Institutes of Health and the National Cancer Institute.

Media Contact: Kelly Schlageter, kelly.schlageter@inova.org

#   #   #